

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

**APPOINTMENT OF DEPUTY GENERAL MANAGER
AND
CHANGE OF MEMBER OF THE REMUNERATION COMMITTEE**

Appointment of deputy general manager

The Board is pleased to announce that Ms. Wei has been appointed as the deputy general manager of the Company with effect from 19 February 2016.

Change of member of the Remuneration Committee

The Board announces that Mr. Huang Ping, an existing executive director, the Board secretary and the joint company secretary of the Company, has been appointed as a replacement member of the Remuneration Committee with effect from 19 February 2016.

Appointment of deputy general manager

The board of directors (the “**Board**”) of Shanghai Haohai Biological Technology Co., Ltd. (the “**Company**”) is pleased to announce that Ms. Wei Xin (“**Ms. Wei**”) has been appointed as the deputy general manager of the Company with effect from 19 February 2016.

Ms. Wei, aged 44, joined the Company in March 2008 as the manager of the medical marketing department. She was promoted to act as the director of the medical marketing department of the Company since January 2011 and the assistant to the general manager of the Company since March 2012. Prior to joining the Company, she was an obstetrician-gynecologist in Shanghai Sixth Renmin Hospital* (上海第六人民醫院) from July 1995 to November 2002. From December 2002 to January 2007, she was the manager of the medical marketing department at Cinkate Pharmaceutical and Chemical Intermediates (Shanghai) Company Limited* (欣凱醫藥化工中間體(上海)有限公司), a company principally engaged in the development and production of

pharmaceutical and chemical intermediates. Ms. Wei obtained a bachelor degree in clinical medicine from the then Shanghai Tiedao University* (上海鐵道大學) in June 1995, the practising doctor qualification in the People's Republic of China in May 1999 and the attending physician qualification in December 2001.

Save as disclosed above, Ms. Wei does not hold any other position in the Company and its subsidiaries (the “**Group**”), and did not hold any directorships in public companies listed in Hong Kong or any other major exchanges in the last three years preceding the date of her appointment. Ms. Wei does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Ms. Wei has no interests in the shares of the Company which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, there are no other matters relating to the appointment of Ms. Wei that should be brought to the attention of the shareholders of the Company, and there is no other information that should be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Ms. Wei has entered into a service contract with the Company as the deputy general manager for a term of 3 years commencing from 19 February 2016, pursuant to which Ms. Wei will be entitled to an annual salary of Renminbi 300,000 (before tax). The remuneration package of Ms. Wei is determined with reference to her background, experience and duties and responsibilities with the Group and the prevailing market conditions, and shall be subject to the review by the Board and the remuneration committee from time to time.

Change of member of the Remuneration Committee

Reference is made to the announcement of the Company on 17 January 2016. The Board announces that Mr. Huang Ping, an existing executive director, the Board secretary and the joint company secretary of the Company, has been appointed as a replacement member of the remuneration committee of the Company (the “**Remuneration Committee**”) with effect from 19 February 2016 until the end of the term of current session of the Board.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Chairman
Hou Yongtai

Shanghai, the PRC, 19 February 2016

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Mr. Huang Ping and Ms. Chen Yiyi; the non-executive directors of the Company are Ms. You Jie and Mr. Gan Renbao; and the independent non-executive directors of the Company are Mr. Chen Huabin, Mr. Shen Hongbo, Mr. Li Yuanxu, Mr. Zhu Qin and Mr. Wong Kwan Kit.

** For identification purpose only*